|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
66,383,000 |
Market
Cap: |
1.53(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$16.53 - $28.72 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 2 |
Insider 3/6 Months : 2.6 |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Xencor is a clinical-stage biopharmaceutical company focused on discovering and developing engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. Co. is developing a portfolio of clinical-stage XmAb® drug candidates from its protein engineering technology platforms. Co.'s XmAb bispecific Fc drug candidates include: Vudalimab (XmAb717), which is a bispecific antibody that targets PD-1 and CTLA-4 and for patients with metastatic castration-resistant prostate cancer and other solid tumor types; and Plamotamab, which is a bispecific antibody that targets CD20, an antigen on B-cell tumors, and CD3, an activating receptor on T cells.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
53 |
53 |
53 |
Total Buy Value |
$0 |
$1,013 |
$1,013 |
$1,013 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
51,988 |
151,096 |
184,593 |
219,438 |
Total Sell Value |
$1,215,592 |
$3,206,005 |
$4,083,291 |
$5,152,397 |
Total People Sold |
6 |
6 |
6 |
7 |
Total Sell Transactions |
10 |
12 |
13 |
28 |
End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Valente Nancy |
EVP, Chief Development Officer |
|
2024-05-02 |
4 |
S |
$23.58 |
$111,872 |
D/D |
(4,745) |
55,115 |
|
5% |
|
Cornelissen Bart Jan |
SR. VICE PRESIDENT & CFO |
|
2024-04-09 |
4 |
A |
$0.00 |
$0 |
D/D |
42,265 |
42,265 |
|
- |
|
Desjarlais John R |
SR. VICE PRESIDENT & CSO |
|
2024-03-11 |
4 |
S |
$23.50 |
$30,082 |
D/D |
(1,280) |
186,433 |
|
3% |
|
Kuch John J |
SR. VICE PRESIDENT & CFO |
|
2024-03-11 |
4 |
S |
$23.50 |
$19,953 |
D/D |
(849) |
121,070 |
|
3% |
|
Eckert Celia |
SVP, GENERAL COUNSEL |
|
2024-03-11 |
4 |
S |
$23.50 |
$19,977 |
D/D |
(850) |
45,465 |
|
3% |
|
Dahiyat Bassil I |
PRESIDENT & CEO |
|
2024-03-11 |
4 |
S |
$23.50 |
$64,418 |
D/D |
(2,741) |
351,894 |
|
3% |
|
Gustafson Kurt A |
Director |
|
2024-03-06 |
4 |
S |
$23.18 |
$324,453 |
D/D |
(14,000) |
6,007 |
|
6% |
|
Gustafson Kurt A |
Director |
|
2024-03-06 |
4 |
OE |
$10.73 |
$160,950 |
D/D |
15,000 |
20,007 |
|
- |
|
Dahiyat Bassil I |
PRESIDENT & CEO |
|
2024-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
54,538 |
354,635 |
|
- |
|
Dahiyat Bassil I |
PRESIDENT & CEO |
|
2024-03-05 |
4 |
S |
$23.43 |
$293,519 |
D/D |
(12,528) |
300,097 |
|
2% |
|
Kuch John J |
SR. VICE PRESIDENT & CFO |
|
2024-03-05 |
4 |
S |
$23.43 |
$104,821 |
D/D |
(4,474) |
121,919 |
|
2% |
|
Desjarlais John R |
SR. VICE PRESIDENT & CSO |
|
2024-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
20,724 |
187,713 |
|
- |
|
Desjarlais John R |
SR. VICE PRESIDENT & CSO |
|
2024-03-05 |
4 |
S |
$23.43 |
$155,311 |
D/D |
(6,629) |
166,989 |
|
2% |
|
Eckert Celia |
SVP, GENERAL COUNSEL |
|
2024-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
13,089 |
46,315 |
|
- |
|
Eckert Celia |
SVP, GENERAL COUNSEL |
|
2024-03-05 |
4 |
S |
$23.43 |
$91,186 |
D/D |
(3,892) |
33,226 |
|
2% |
|
Valente Nancy |
EVP, Chief Development Officer |
|
2024-03-05 |
4 |
A |
$0.00 |
$0 |
D/D |
19,634 |
59,860 |
|
- |
|
Desjarlais John R |
SR. VICE PRESIDENT & CSO |
|
2024-02-14 |
4 |
OE |
$11.05 |
$131,970 |
D/D |
11,943 |
173,618 |
|
- |
|
Desjarlais John R |
SR. VICE PRESIDENT & CSO |
|
2024-02-13 |
4 |
AS |
$19.38 |
$1,048,743 |
D/D |
(54,108) |
161,675 |
|
20% |
|
Desjarlais John R |
SR. VICE PRESIDENT & CSO |
|
2024-02-13 |
4 |
OE |
$11.05 |
$752,030 |
D/D |
68,057 |
215,783 |
|
- |
|
Gorman Kevin Charles |
Director |
|
2024-02-13 |
4 |
B |
$19.12 |
$1,013 |
D/D |
53 |
5,060 |
2.31 |
17% |
|
Dahiyat Bassil I |
PRESIDENT & CEO |
|
2023-12-29 |
4 |
S |
$20.93 |
$941,670 |
D/D |
(45,000) |
312,929 |
|
-6% |
|
Dahiyat Bassil I |
PRESIDENT & CEO |
|
2023-12-29 |
4 |
OE |
$11.05 |
$718,261 |
D/D |
65,001 |
357,929 |
|
- |
|
Dahiyat Bassil I |
PRESIDENT & CEO |
|
2023-06-21 |
4 |
S |
$26.19 |
$877,286 |
D/D |
(33,497) |
292,216 |
|
35% |
|
Dahiyat Bassil I |
PRESIDENT & CEO |
|
2023-06-21 |
4 |
OE |
$4.25 |
$323,051 |
D/D |
76,012 |
325,713 |
|
- |
|
Gustafson Kurt A |
Director |
|
2023-06-20 |
4 |
A |
$0.00 |
$0 |
D/D |
5,007 |
5,007 |
|
- |
|
334 Records found
|
|
Page 1 of 14 |
|
|